June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Lutein supplementation leads to a decreased level of circulating complement factors
Author Affiliations & Notes
  • Tos TJM Berendschot
    University Eye Clinic Maastricht, Maastricht, Netherlands
  • Yuan Tian
    University Eye Clinic Maastricht, Maastricht, Netherlands
  • Ian Murray
    Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
  • Maria Makridaki
    Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
  • Rob LP van der Veen
    University Eye Clinic Maastricht, Maastricht, Netherlands
  • Aize Kijlstra
    University Eye Clinic Maastricht, Maastricht, Netherlands
  • Footnotes
    Commercial Relationships Tos TJM Berendschot, None; Yuan Tian, None; Ian Murray, None; Maria Makridaki, None; Rob LP van der Veen, None; Aize Kijlstra, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4124. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tos TJM Berendschot, Yuan Tian, Ian Murray, Maria Makridaki, Rob LP van der Veen, Aize Kijlstra; Lutein supplementation leads to a decreased level of circulating complement factors. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4124.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Lutein is selectively taken up by the primate retina and plays an important role as a filter for harmful blue light and as an antioxidant. Recent studies have shown that lutein has systemic anti-inflammatory properties. Whether lutein affects activation of the complement system has not yet been addressed and was the purpose of the study described here.

Methods: Eighty-two subjects with signs of early macular degeneration were randomly assigned to receive either a 10 mg lutein supplement or a placebo during one year. EDTA blood samples were collected at 0, 4, 8 and 12 months. Complement Factor D (CFD), a rate limiting component of the alternative pathway of complement activation and the complement activation products C5a and C3d were determined in the plasma samples by ELISA.

Results: A significant 0.12 μg/ml monthly decrease in plasma CFD concentration was observed in the lutein group (p<0.001), resulting in a 61% decrease from 2.33 μg/ml at baseline to 0.91 μg/ml at 12 months. The C5a concentration showed a significant 0.061 ng/ml monthly decrease in the lutein group (p<0.001) resulting in a 35% decrease from 2.07 ng/ml at baseline to 1.58 ng/ml at 12 months. The C3d concentration showed a significant 0.24 μg/ml monthly decrease in the lutein group (p=0.001) that gave rise to a 9% decrease from 15.9 μg/ml at baseline to 14.6 μg/ml at 12 months. No significant changes were observed in the placebo group.

Conclusions: Lutein supplementation markedly decreases circulating levels of the complement factors CFD, C5a and C3d levels, offering a simple method to control the inflammatory pathway of the innate immune system.

Keywords: 412 age-related macular degeneration • 557 inflammation • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×